Metsera, ARCH Venture-Backed Weight-Loss Drug Developer, Files for IPO
ARCH-backed weight-loss drug developer Metsera files for IPO despite widening losses, aiming to capitalize on the booming obesity treatment market. The biotech company seeks funding to advance its lead GLP-1 drug candidate, MET-097i, into further clinical trials.
Metsera, ARCH Venture-Backed Weight-Loss Drug Developer, Files for IPO Read More »